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A B S T R A C T
Objectives: This study was designed to validate the analytical performance of the new Gentian
particle-enhanced enhanced turbidimetric immunoassay (PETIA) for measuring neutrophil
gelatinase-associated lipocalin (NGAL) in serum samples.
Design and methods: Analytical validation of the Gentian NGAL assay was carried out on a Roche
Cobas c501 and was based on assessment of limit of blank (LOB), limit of detection (LOD),
functional sensitivity, imprecision, linearity and concordance with the BioPorto NGAL test.
Results: The LOB and LOD of Gentian NGAL were found to be 3.8 ng/mL and 6.3 ng/mL,
respectively. An analytical coeﬃcient of variation (CV) of 20% corresponded to a NGAL value of
10 ng/mL. The intra-assay and inter-assay imprecision (CV) was between 0.4 and 5.2% and 0.6
and 7.1% and the total imprecision (CV) was 3.7%. The linearity was optimal at NGAL
concentrations between 37 and 1420 ng/mL (r=1.00; p< 0.001). An excellent correlation was
observed between values measured with Gentian NGAL and BioPorto NGAL in 74 routine serum
samples (r=0.993). The mean percentage bias of the Gentian assay versus the Bioporto assay was
+3.1% (95% CI, +1.6% to +4.5%).
Conclusions: These results show that Gentian NGAL may be a viable option to other commercial
immunoassays for both routine and urgent assessment of serum NGAL.
1. Introduction
The neutrophil gelatinase-associated lipocalin (NGAL), also known as lipocalin-2, is a single disulﬁde-bridged protein of 178
aminoacids with a molecular mass of 22 kDa, increasing to 25 kDa after glycosylation [1]. The protein can be detected in both serum
and urine in three main molecular forms; a 25-kD monomer, a 45-kD disulﬁde-linked homodimer and a 135-kD heterodimer, in
which the protein is covalently linked to matrix metalloproteinase 9 (MMP-9) by means of a single intermolecular disulﬁde bridge
[1]. Although NGAL was originally detected in activated neutrophils, its expression was later identiﬁed in many other tissues and
organs including the kidney, lungs, intestine and prostate. More recently, the ectopic expression of NGAL has been reported in
patients with various malignancies such as kidney, colorectal, gastric, pancreatobiliary, hepatic, breast, gynecological and
hematologic cancers [2].
The clinical use of NGAL has gained attention since 2003, when it was convincingly shown that the concentration of this
biomarker increases considerably immediately after acute kidney injury (AKI) [3]. Since then, several studies have conﬁrmed that
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NGAL may be considered as an early and reliable biomarker of AKI in various clinical settings [4–7].
Ideally, a candidate biomarker of AKI should have many important characteristics, such as being measurable with a noninvasive,
easy, rapid and inexpensive technique and displaying high sensitivity and speciﬁcity for AKI. It should also permit early detection of
AKI, provide information about severity and reversibility of disease, and predict response to treatment and clinical outcome [8].
Among the various potential biomarkers of AKI, which also include kidney injury molecule-1 (KIM-1), N-acetyl-β-d-glucosaminidase
(NAG), liver fatty acid-binding protein (L-FAB), and interleukin-18 (IL-8), NGAL has been shown to be the most promising, and is the
only one for which fully-automated assays have become available to date [8]. The availability of quick and reliable automated
immunoassays allows rapid laboratory assessment and timely communication of test results to clinicians, enabling early diagnosis of
AKI and reliable prediction of outcome. The measurement of NGAL in serum or plasma is also considered to be more convenient than
measurement in urine, since urine output may be considerably reduced in patients with AKI. The reliability of urine measurement is
also challenged by several preanalytical issues such as the poor standardization of urine collection procedures compared to those for
venous blood and the possible contamination with leukocytes in patients with urinary infections, which may ultimately decrease the
diagnostic eﬃciency of this biomarker [9]. The clinical signiﬁcance of measuring NGAL has also been recently highlighted in
conditions other then AKI, such as acute bacterial meningitis [10] and bacterial peritonitis [11]. Notably, a growing number of
studies have reported that NGAL may be used as an eﬃcient biomarker for early diagnosis and predicting the clinical outcome of
certain types of cancer [12–14].
Therefore, the present study was designed to validate the analytical performance of Gentian NGAL, a new fully-automatable
immunoassay for measuring NGAL in human serum and urine.
2. Materials and methods
2.1. Assay characteristics
Gentian NGAL (Gentian, Moss, Norway) is a particle-enhanced enhanced turbidimetric immunoassay (PETIA), which can be
applied to a vast array of automated clinical chemistry analyzers. According to the assay principle, urine or plasma samples are mixed
with a solution containing anti-NGAL immunoparticles. The NGAL present in the sample aggregates with the anti-NGAL
immunoparticles to generate immunocomplexes, which increase the turbidity of the solution. Light absorbance, measured between
480 and 560 nm, is directly proportional to the concentration of the molecule in the test sample. The NGAL concentration is
calculated form a 6-point pre-diluted standard calibration curve, with calibrators values comprised between 0 and 3168 ng/mL. The
manufacturers’ literature states that the calibrators contain NGAL of recombinant origin, with values assigned according to Gentian's
internal value transfer protocol, based on published methods [15]. In this study, the method has been applied for use on a Roche
Cobas c501 module (Roche Diagnostics, Indianapolis, IN, USA). The quoted NGAL serum/plasma reference range is 13.7–104.6 ng/
mL, the total sample volume needed for the assay is 3 μL and test results are available in 10 min.
2.2. Analytical performance
The analytical validation of Gentian NGAL PETIA consisted of calculation of limit of blank (LOB), limit of detection (LOD) and
functional sensitivity, and estimation of inter-assay and intra-assay imprecision, linearity, and correlation with another widely used
NGAL PETIA (BioPorto Diagnostics).
The calculation of the LOB and LOD was carried out as described by Armbruster and Pry [16], as follows: [LOB]=mean value
+1.645* standard deviation (SD) of 10 consecutive replicates of saline; [LOD]=LOB +1.645* SD of 10 replicates of a routine serum
sample with the lowest measurable NGAL concentration. The functional sensitivity of the assay was deﬁned as the lowest NGAL
concentration which could be measured with an imprecision (CV) ≤20%. This value was determined by performing nine serial
dilutions in sample buﬀer (i.e., from 1:2 to 1:512) of a routine serum sample with NGAL concentration of 1485 ng/mL. Each dilution
was measured in 10 replicates and the imprecision was calculated for each dilution. A model ﬁt was constructed to extrapolate the
NGAL value associated with a CV of 20%.
The imprecision studies were performed using three serum pools selected for low (~40 ng/mL), intermediate (~260 ng/mL) and
high (~1465 ng/mL) NGAL concentrations. Within-and between-run imprecision was respectively assessed in 20 consecutive runs
and over 10 consecutive working days, using the same calibration curve and identical reagent lots. Results were reported as
coeﬃcient of variation (CV%). The total analytical imprecision was calculated according to the formula proposed by Krouwer and
Rabinowitz [17].
The linearity of the assay was tested as follows: a routine serum sample with high NGAL concentration (1420 ng/mL) was serially
diluted at ﬁxed ratios (1:9; 2:8; 3:7; 4:6; 5:5; 6:4; 7:3, 8:2; 9:1) with another routine serum sample with a low NGAL concentration
(37 ng/mL), to produce samples with a clinically signiﬁcant range of NGAL concentrations in serum. The serial dilutions were then
measured in duplicate and theoretical values were calculated from the measured values of undiluted specimens.
2.3. Method comparison
The comparison study was performed using routine serum samples referred from the emergency department to the laboratory for
assessment of serum creatinine, over one working morning. All samples were tested within 2 h of collection. The results of the
Gentian NGAL assay were compared with those obtained on the same sample with BioPorto NGAL Test (BioPorto Diagnostics A/S,
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Gentofte, Denmark), on the same Roche Cobas c501 (Roche Diagnostics). The technical and analytical characteristics of the BioPorto
assay have been described elsewhere [18]. Brieﬂy, Bioporto NGAL Test is another PETIA for quantitative assessment of NGAL in
human urine, EDTA plasma and serum samples, that can be adapted for use on a variety of automated clinical chemistry analyzers.
The intra-assay, inter-assay and total imprecision for the BioPorto NGAL Test was found to be 1.0–2.3%, 1.2–2.0% and 2.2%,
respectively. The BiPorto NGAL Test has also been shown to display a highly signiﬁcant agreement with the current reference
chemiluminescent immunoassay (Abbott Architect NGAL; Abbott Diagnostics, Lake Forest, IL, USA) (r=0.925; p< 0.001) [18].
2.4. Statistics and ethical approval
The linearity of the Gentian NGAL assay was tested by calculation of Spearman's correlation coeﬃcient (r) and using Passing and
Bablok regression analysis. The agreement of values obtained using Gentian NGAL and BiPorto NGAL was tested with Mann-Whitney
test for paired samples, Spearman's correlation, Passing and Bablok regression analysis and Bland and Altman plot analysis. The
statistical analysis was performed using Analyse-It (Analyse-it Software Ltd, Leeds, UK), a statistical add-in for Microsoft Excel. The
evaluation of Gentian NGAL was performed using pre-existing serum samples collected in evacuated blood tubes containing gel and
clot activator (Vacutest 3.5 mL, 75×13 mm; Kima, Padova, Italy), which were referred for routine laboratory testing. The entire
study was carried out for purposes of ISO 15189:2012 accreditation, in accordance with the Declaration of Helsinki, under the terms
of relevant local legislation, and was approved by the local Institutional Review Board (University Hospital of Verona, Verona, Italy).
3. Results
The LOB and LOD of Gentian NGAL were found to be 3.8 ng/mL and 6.3 ng/mL, respectively. The estimation of functional
sensitivity is shown in Fig. 1. A 20% CV of the assay corresponded exactly to a NGAL serum concentration of 10 ng/mL. The data
obtained from the imprecision studies using serum pools with low, medium and high NGAL values are shown in Table 1. The intra-
assay and inter-assay imprecision (CV) for high and low serum pools ranged between 0.4 and 5.2% and between 0.6 and 7.1%. The
total analytical imprecision (CV) was 3.7%. The linearity of the assay was virtually perfect over NGAL concentrations between 37 and
1420 ng/mL (r=1.00; p<0.001). The Spearman correlation coeﬃcient was 1.00 (p< 0.001) and the equation of the Passing and
Bablok regression line was y=1.00x+0.5.
An excellent correlation was observed when comparing values measured with Gentian NGAL and BioPorto NGAL in 74 routine
samples with NGAL concentrations between 90 and 1501 ng/mL (r=0.993; 95% CI, 0.988–0.995; p<0.001). The equation of the
Passing and Bablok regression line was [Gentian NGAL]=0.99×[BioPorto NGAL]+28. The results of the Bland and Altman plot
Fig. 1. Calculation of the functional sensitivity (concentration at CV=20%) of Gentian NGAL.
Table 1
Intra- and inter-assay imprecision of Gentian NGAL.
Serum pool Intra-assay Inter-assay
Conc. (ng/mL) CV Conc. (ng/mL) CV
Pool low 39.1± 2.0 5.2% 30.0± 2.1 7.1%
Pool medium 257.9± 2.7 1.1% 241.3±3.0 1.2%
Pool high 1465.4±5.4 0.4% 1414.8± 9.1 0.6%
NGAL, neutrophil gelatinase-associated lipocalin; CV, coeﬃcient of variation. Conc, NGAL concentration in pool.
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analysis are shown in Fig. 2. The mean percentage bias of Gentian NGAL versus BioPorto NGAL was +3.1% (95% CI: +1.6% to
+4.5%). The diﬀerence between NGAL concentrations obtained with the two assays was found to be statistically signiﬁcant
(p<0.001).
4. Discussion
The measurement of biomarkers of tubular injury for diagnosis and prognosis of AKI is becoming very popular in clinical
laboratories. Among the various available biomarkers, NGAL has been found to have the best diagnostic and prognostic eﬃciency [8],
and is also the only AKI biomarker for which fully-automated immunoassays are currently available. The clinical applications of this
biomarker have recently broadened to include diagnosis and monitoring of other human diseases, such as cancers [2] and bacterial
infections [10,11]. In the case of AKI, a ﬁrst meta-analysis, published in 2009 by the NGAL Meta-analysis Investigator Group and
including 19 studies and 2538 patients (487 of whom [19.2%] developed AKI) showed that the area under the receiver operating
characteristics curve (AUC/ROC) for predicting AKI was as high as 0.82 (95% CI, 0.73–0.89) [5]. The measurement of NGAL was also
found to be useful for predicting renal replacement therapy (AUC/ROC, 0.78; 95% CI, 0.65–0.92) and in-hospital mortality (AUC/
ROC, 0.71; 95% CI, 0.53–0.75). Notably, the diagnostic accuracy of plasma or serum NGAL was found to be similar to that of urine
NGAL. A more recent (2016) meta-analysis, including 24 studies and 4066 patients, substantially conﬁrmed these ﬁndings,
concluding that the AUC of NGAL was as high as 0.86±0.02 for early diagnosis of AKI [6]. In the same year, an additional meta-
analysis of ten prospective studies involving nearly 30,000 participants also concluded that, among the various urinary tubular injury
biomarkers, only NGAL may be an independent predictor of end stage renal disease in patients with chronic kidney disease [7].
Until recently, the availability of commercial methods for measuring NGAL in serum, plasma or urine was limited, mainly
consisting of a fully-automated immunoassay (BioPorto NGAL Test) for use on conventional clinical chemistry analyzers [18,19] and
another assay available only on the immunochemistry platform Abbott Architect [20]. Now that Gentian NGAL PETIA has been
introduced to the market, we have validated its analytical performance on the Roche Cobas c501, a widely used clinical chemistry
analyzer. Our results suggest that Gentian NGAL assay displays excellent analytical performance. The estimated LOD, LOB and the
analytical sensitivity were optimal for the reference range of serum NGAL (13.7–104.6 ng/mL). The total imprecision (3.7%) was
slightly worse than that of the BioPorto NGAL Test (2.2%) but comparable to that of the Abbott Architect NGAL (2.9–3.7%). Much
better imprecision results could have been achieved calculating total imprecision on data obtained only on medium and high serum
pools (1.2%). The linearity was excellent over a range of NGAL concentration between 37 and 1420 ng/mL. The comparison with
BioPorto NGAL Test, the current reference immunoassay, was acceptable, yielding a clinically insigniﬁcant bias (~3%) compared to
the intra-individual biological variability of this biomarker (11%) [20].
5. Conclusions
The result of our analytical validation show that Gentian NGAL may be a viable option for both routine and urgent assessment of
serum NGAL. Additional advantages are: the very fast turnaround time (results are available in approximately 10 min compared to
35 min for the Abbott Architect NGAL and nearly 2 h with manual ELISAs), acceptable imprecision and optimal linearity in the
clinically signiﬁcant range of NGAL concentrations. The possibility of widespread implementation of this test on a wide array of
clinical chemistry platforms may also permit the concomitant measurement of NGAL and other biomarkers of renal function (e.g.,
creatinine or blood urea nitrogen) on a single blood sample, so optimizing laboratory workﬂow and saving economic resources.
Finally, the bias observed when comparing Gentian NGAL results with those obtained using BioPorto NGAL Test was modest (less
than biological variation), thus providing a solid background for further studies addressing the possibility of using both methods
Fig. 2. Bland and Altman plot analysis of correlation between BioPorto NGAL test and Gentian NGAL (horizontal lines show mean bias and 95% CI of bias).
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interchangeably within a network of clinical laboratories.
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